Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coagulation parameters during biologic dose reduction in inflammatory arthritis
NL-OMON43241Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Jul 2016
- Countries
- 1
01
Overview
Open-label trial in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) (3 cohorts), sponsored by Jan van Breemen Institute. Primary endpoints: Prothrombin fragments 1 and 2, Thrombin-antithrombin complexes and 2 more. Started Jul 2016; status: recruiting.
02
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON43241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43241.